Haemonetics Corporation (HAE)

Debt-to-capital ratio

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Long-term debt US$ in thousands 797,564 856,849 748,662 751,381 754,102 756,826 759,552 763,141 559,441 633,118 698,043 767,345 690,592 292,721 297,016 296,893 305,513 309,738 313,984 318,144
Total stockholders’ equity US$ in thousands 959,959 943,319 893,660 864,616 817,997 775,979 729,009 770,423 749,424 730,775 698,549 677,080 731,670 719,152 667,923 608,569 587,109 574,580 583,754 590,966
Debt-to-capital ratio 0.45 0.48 0.46 0.46 0.48 0.49 0.51 0.50 0.43 0.46 0.50 0.53 0.49 0.29 0.31 0.33 0.34 0.35 0.35 0.35

March 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $797,564K ÷ ($797,564K + $959,959K)
= 0.45

The debt-to-capital ratio of Haemonetics Corporation has fluctuated over the periods provided, ranging from a low of 0.29 to a high of 0.53. Generally, the ratio has shown a tendency to vary around the mid-0.4 range. This indicates that, on average, around 40-50% of the company's capital structure is financed by debt, with the remainder coming from equity.

It is worth noting that the ratio has experienced some volatility, with fluctuations potentially reflecting changes in the company's debt levels relative to its total capital. A lower ratio typically suggests a lower level of financial risk, as it indicates that the company relies less on debt financing. Conversely, a higher ratio may imply higher financial risk due to a larger proportion of debt in the capital structure.

Overall, it would be essential to monitor the trend in the debt-to-capital ratio over time to assess Haemonetics Corporation's evolving financial leverage and risk profile.


Peer comparison

Mar 31, 2024